According to a recent LinkedIn post from Sequel Med Tech, the company is highlighting the launch of an automated insulin delivery system that combines its twiist platform with the Eversense 365 continuous glucose monitoring technology from Senseonics and is powered by Tidepool software. The post describes twiist as the first AID system compatible with Eversense 365, which is characterized as the only one-year CGM currently available and is indicated for adults with diabetes.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post suggests this integration is intended to reduce the burden of frequent sensor changes and device re-pairing while preserving CGM accuracy, targeting people with Type 1 diabetes aged 6 and older in the U.S. market. For investors, this type of ecosystem partnership may strengthen Sequel Med Tech’s positioning in the diabetes technology segment, potentially increasing product differentiation and supporting recurring revenue opportunities if adoption and reimbursement coverage expand.
By tying an AID system to a long-duration implantable sensor and an established data platform, the post implies Sequel Med Tech is pursuing a strategy focused on long-term disease management rather than short-term device cycles. If the combined solution gains clinical and patient traction, it could enhance competitive dynamics versus traditional CGM-plus-pump offerings and may improve the company’s appeal as a partner in the broader digital health and diabetes-care landscape.